Overview

FTIH of ECC5004 in Healthy Participants

Status:
Recruiting

Trial end date:
2023-10-06

Target enrollment:

Participant gender:

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus

Phase:

Phase 1

Details

Lead Sponsor:

Eccogene